BioLineRx Ltd.
BLRX
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarciā¦ read more
Healthcare
Biotechnology
15 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$2.66
Price-5.78%
-$0.16
1Y
Price
Market Cap
$11.562m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-471.7%
EBITDA Margin-541.1%
Net Profit Margin-479.3%
Free Cash Flow Margin-471.7%
EBITDA Margin-541.1%
Net Profit Margin-479.3%
Free Cash Flow MarginRevenue
$1.403m
+18.0%
1y CAGR+141.7%
3y CAGR+106.3%
5y CAGREarnings
-$8.892m
-650.8%
1y CAGR-159.6%
3y CAGR-155.4%
5y CAGREPS
-$2.12
-631.0%
1y CAGR-149.8%
3y CAGR-136.2%
5y CAGRBook Value
$20.835m
$38.797m
Assets$17.962m
Liabilities$9.070m
DebtDebt to Assets
23.4%
-1.1x
Debt to EBITDAFree Cash Flow
-$7.823m
+4.2%
1y CAGR-2.1%
3y CAGR+1.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company